Search Results

Eric Trinquet, Director of Research and Development at Revvity.   A GPCR Internalization Tool Designed for Real Research Needs Built on more than two decade A GPCR Internalization Tool Designed for Real Research Needs s of GPCR assay innovation , pHSense™  was developed to overcome GPCR  is a global nonprofit platform advancing GPCR research  through education, community, and platform Its GPCR research tools  support discovery teams and academic labs with precision reagents and validated

A Detour Through Immunology Her growing interest in addiction led her to the NIH’s Perinatology Research to patient-centered research. “It really forced me to kind of patch up all my immunology holes and then apply them. I came away from that job with just a whole new appreciation for immunology and for pregnancy. The Importance of Passion in Research Catherine's journey highlights the importance of passion in research

The GPCR ship is setting sail on a grand voyage across the vast ocean of research. Symposia 💲 Discounted GPCR courses GPCR Forum Start an engaging discussion or request help in your research Scientist, Medicinal Chemistry PhD fellowship in GPCR mechanosensing Senior Scientist, GPCR Pharmacology Research Receptor-dependent influence of R7 RGS proteins on neuronal GIRK channel signaling dynamics GPCRs in Oncology and Immunology hepatocellular carcinoma cells via inhibition of the c-Jun N-terminal kinase Methods & Updates in GPCR Research

In a recent study on TAAR1, a GPCR linked to central nervous system disorders, researchers compared the

occurring Δ9-tetrahydrocannabinolderivatives to cannabinoid CB1 and CB2 receptors, Pharmacological Research

Celtarys Research Joins Dr. GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. Full Breakdown of the Latest in GPCR Research Want detailed insights? Dive into this week’s research, tools, and biotech updates all in one place.

January 2022 Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia royalties PARIS & OXFORD, England & BOSTON--Sanofi and Exscientia announced today a groundbreaking research novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology

This is Lucía from the Celtarys Research chemistry team.  For our very first post in this ecosystem, we wanted to highlight a huge part of our work at Celtarys Research

Despite their immense potential, utilizing FRET and BRET sensors in GPCR research comes with challenges In conclusion, FRET and BRET-based sensors have transformed the landscape of GPCR research, offering

Thus, developing assays for commercially available probes such as CELT-419 would facilitate research For example, a Cy5-labelled fluorescent ligand with the same pharmacophore is available from Celtarys Research development of measurement methods can increase the quality and quantity of both fundamental receptor research

December 2021 "Meet Peter McNamara, Ph.D., Tectonic’s SVP, Head of Research.

March 2022 ERNEST has established an Emergency Fund for Ukrainian researchers. "General Eligibility Researchers affiliated to any legal entity in Ukraine (for example, schools and universities, research centers, governmental institutions, or private companies) Deadlines Start of the who have been recently displaced by the war, or those who can travel to institutions participating in Our scientific perspective is broad, and we are happy to consider any research proposals from those in

June 2022 "CRN04894 Selected for Oral Presentation SAN DIEGO, June 8, 2022 — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study." Read more at the source #DrGPCR #GPCR #IndustryNews

Hello GPCR Trailblazers, This week, we’re spotlighting Celtarys Research, our newest partner, featured GPCR will help researchers move faster with custom fluorescent ligands, translational insight, and tool-enabled Introducing Celtarys - Probe Development via Conjugation Strategies   Celtarys Research's first article Constitutive ghrelin receptor activity, not dimerization or ligand binding —reverses dopamine D2 signaling Explore this week’s research, tools, and biotech insights in one place. The insights are ready.

Watch Episode 170 What We’re Missing in Pain Research In GPCR drug discovery, receptors typically steal where, as a mouse was starting to enter what we consider the chronic pain range, the mice that were constitutively against chronic pain. ___________ Keyword Cloud: RGS4 , GPCR data platform , GPCR training program , pain research

August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for US $900,000) of additional research funding.

September 2022 Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation "Gut intraepithelial lymphocytes (IELs) are thought to calibrate glucagon-like peptide 1 (GLP-1) bioavailability, thereby regulating systemic glucose and lipid metabolism. Here, we show that the gut IEL GLP-1 receptor (GLP-1R) is not required for enteroendocrine L cell GLP-1 secretion and glucose homeostasis nor for the metabolic benefits of GLP-1R agonists (GLP-1RAs). Instead, the gut IEL GLP-1R is essential for the full effects of GLP-1RAs on gut microbiota. Moreover, independent of glucose control or weight loss, the anti-inflammatory actions of GLP-1RAs require the gut IEL GLP-1R to selectively restrain local and systemic T cell-induced, but not lipopolysaccharide-induced, inflammation. Such effects are mediated by the suppression of gut IEL effector functions linked to the dampening of proximal T cell receptor signaling in a protein-kinase-A-dependent manner. These data reposition key roles of the L cell-gut IEL GLP-1R axis, revealing mechanisms linking GLP-1R activation in gut IELs to modulation of microbiota composition and control of intestinal and systemic inflammation." Read more at the source #DrGPCR #GPCR #IndustryNews

Watch Episode 172 The Bigger Picture: GPCR Science Meets Public Health At its core, Catherine Demery’s research street-level contamination rising faster than medicine can adapt, Catherine’s work shows why overdose research Catherine’s research confronts this problem head-on by asking: What actually happens to breathing when From Street Samples to Lab Models What makes Catherine’s research particularly powerful is how it stays Without research that keeps pace, clinical tools will always be one step behind.

In the realm of molecular research, precise interpretation is crucial; a misread curve can lead to lost

October 2022 β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the same GPCR in living cells "β-arrestins mediate regulatory processes for over 800 different G protein-coupled receptors (GPCRs) by adopting specific conformations that result from the geometry of the GPCR-β-arrestin complex. However, whether β-arrestin1 and 2 respond differently for binding to the same GPCR is still unknown. Employing GRK knockout cells and β-arrestins lacking the finger-loop-region, we show that the two isoforms prefer to associate with the active parathyroid hormone 1 receptor (PTH1R) in different complex configurations ("hanging" and "core"). Furthermore, the utilisation of advanced NanoLuc/FlAsH-based biosensors reveals distinct conformational signatures of β-arrestin1 and 2 when bound to active PTH1R (P-R*). Moreover, we assess β-arrestin conformational changes that are induced specifically by proximal and distal C-terminal phosphorylation and in the absence of GPCR kinases (GRKs) (R*). Here, we show differences between conformational changes that are induced by P-R* or R* receptor states and further disclose the impact of site-specific GPCR phosphorylation on arrestin-coupling and function." Read more at the source #DrGPCR #GPCR #IndustryNews Subscribe to the Dr. GPCR Newsletter

Yet that summer research placement cracked open a new reality: the thrill of asking questions no one She went from reluctant intern to global researcher shaping how we understand GPCR spatial signaling. By 2011, she had established her own group within the Drug Discovery Biology theme at Monash Institute This pivot reflects a universal research truth: origin stories evolve—but the spark remains . For GPCR research, leaders like Michelle are showing what happens when we follow the signal all the way

October 2022 Cholesterol-Dependent Dynamics of the Serotonin1A Receptor Utilizing Single Particle Tracking: Analysis of Diffusion Modes "G protein-coupled receptors (GPCRs) are signaling hubs in cell membranes that regulate a wide range of physiological processes and are popular drug targets. Serotonin1A receptors are important members of the GPCR family and are implicated in neuropsychiatric disorders. Cholesterol is a key constituent of higher eukaryotic membranes and is believed to contribute to the segregated distribution of membrane constituents into domains. To explore the role of cholesterol in lateral dynamics of GPCRs, we utilized single particle tracking (SPT) to monitor diffusion of serotonin1A receptors under acute and chronic cholesterol-depleted conditions. Our results show that the short-term diffusion coefficient of the receptor decreases upon cholesterol depletion, irrespective of the method of cholesterol depletion. Analysis of SPT trajectories revealed that relative populations of receptors undergoing various modes of diffusion change upon cholesterol depletion. Notably, in cholesterol-depleted cells, we observed an increase in the confined population of the receptor accompanied by a reduction in diffusion coefficient for chronic cholesterol depletion. These results are supported by our recent work and present observations that show polymerization of G-actin in response to chronic cholesterol depletion. Taken together, our results bring out the interdependence of cholesterol and actin cytoskeleton in regulating diffusion of GPCRs in membranes." Read more at the source #DrGPCR #GPCR #IndustryNews

October 2022 Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands targeting G-protein-coupled receptors "Recently, academic and industrial scientific communities involved in kinetics-based drug development have become immensely interested in predicting the drug target residence time. Screening drug candidates in terms of their computationally predicted residence times, which is a measure of drug efficacy in vivo, and simultaneously assessing computational binding affinities are becoming inevitable. Non-equilibrium molecular simulation approaches are proven to be useful in this purpose. Here, we have implemented an optimized approach of combining the data derived from steered molecular dynamics simulations and the Bell-Evans model to predict the absolute residence times of the antagonist ZMA241385 and agonist NECA that target the A2A adenosine receptor of the G-protein-coupled receptor (GPCR) protein family. We have predicted the absolute ligand residence times on the timescale of seconds. However, our predictions were many folds shorter than those determined experimentally. Additionally, we calculated the thermodynamics of ligand binding in terms of ligand binding energies and the per-residue contribution of the receptor. Subsequently, binding pocket hotspot residues that would be important for further computational mutagenesis studies were identified. In the experiment, similar sets of residues were found to be in significant contact with both ligands under study. Our results build a strong foundation for further improvement of our approach by rationalizing the kinetics of ligand unbinding with the thermodynamics of ligand binding." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 "Background: Colorectal cancer is the third most common cancer and requires more prognostic The clinical significance of GPR39 in colon cancer has never been reported. Materials: In our study, we compared GPR39 expression between colon cancers and tumor-adjacent tissues by retrieving TCGA data and detected the expression of GPR39 in colon cancers with qPCR and immunohistochemistry

August 2022 Production of human A 2A AR in lipid nanodiscs for 19 F-NMR and single-molecule fluorescence spectroscopy "We describe production of the human A2A adenosine receptor (A2AAR), a class A G protein-coupled receptor (GPCR) for 19F-NMR and single-molecule fluorescence (SMF) spectroscopy. We explain in detail steps shared between the two sample preparation strategies, including expression and isolation of A2AAR and assembly of A2AAR in lipid nanodiscs and procedures for incorporation of either 19F-NMR or fluorescence probes. Protocols for SMF experiments include sample setup, data acquisition, data processing, and error analysis. For complete details on the use and execution of this protocol, please refer to Wei et al. (2022) and Sušac et al. (2018)." Read more at the source #DrGPCR #GPCR #IndustryNews

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

Until recently, itch pathophysiology was poorly understood and treatments were poorly effective in relieving itch. Current progress in our knowledge of the itch processing, the numerous mediators and receptors involved has led to a large variety of possible therapeutic pathways. Currently, inhibitors of IL-31, IL-4/13, NK1 receptors, opioids and cannabinoids, JAK, PDE4 or TRP are the main compounds involved in clinical trials. However, many new targets, such as Mas-related GPCRs and unexpected new pathways need to be also explored. Read full article

That perspective changed the moment he entered GPCR research . Instead, he acts as an advisor, helping research teams decide where modeling can accelerate progress—and The GPCR Challenge What makes collaboration non-negotiable in GPCR research is the biology itself. Whether in academia or biotech, the future belongs to research groups that can orchestrate ecosystems GPCR Models Don’t Discover Drugs—People Do In GPCR research, the biggest breakthroughs won’t come from

September 2022 "Research on cancer therapies focuses on processes such as angiogenesis, cell signaling last decade, increasing evidence of its antitumoral properties in more than a dozen different types of cancer

September 2022 High GPER expression in triple-negative breast cancer is linked to pro-metastatic pathways and predicts poor patient outcomes "Triple-negative breast cancer (TNBC) is a particularly aggressive It is generally considered that TNBC is an estrogen-independent breast cancer, while a new estrogen receptor